Neurizon Therapeutics Limited (ASX:NUZ)
Australia
· Delayed Price · Currency is AUD 0.1200
-0.0050 (-4.00%)
At close: Apr 24, 2025, 4:00 PM AEST
Neurizon Therapeutics Revenue
Neurizon Therapeutics had revenue of 1.53M AUD in the half year ending December 31, 2024, with 58.65% growth. This brings the company's revenue in the last twelve months to 1.52M, up 97.96% year-over-year. In the fiscal year ending June 30, 2024, Neurizon Therapeutics had annual revenue of 841.71K, down -3.66%.
Revenue (ttm)
1.52M
Revenue Growth
+97.96%
P/S Ratio
37.35
Revenue / Employee
378.95K
Employees
4
Market Cap
56.62M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2024 | 841.71K | -31.94K | -3.66% |
| Jun 30, 2023 | 873.65K | -3.64M | -80.63% |
| Jun 30, 2022 | 4.51M | 853.24K | 23.33% |
| Jun 30, 2021 | 3.66M | -463.19K | -11.24% |
| Jun 30, 2020 | 4.12M | -226.64K | -5.21% |
| Jun 30, 2019 | Pro | Pro | Pro |
| Jun 30, 2018 | Pro | Pro | Pro |
| Jun 30, 2017 | Pro | Pro | Pro |
| Jun 30, 2016 | Pro | Pro | Pro |
| Jun 30, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CSL Limited | 24.61B |
| Pro Medicus | 184.58M |
| Cochlear | 2.31B |
| Sonic Healthcare | 9.33B |
| Telix Pharmaceuticals | 783.21M |
| Ramsay Health Care | 17.12B |
| Ansell | 3.00B |
| Mesoblast | 9.16M |